What is the recommended tapering schedule for a child or young adult with Attention Deficit Hyperactivity Disorder (ADHD) when discontinuing Straterra (atomoxetine) 40mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinuing Strattera (Atomoxetine) 40mg Daily

Atomoxetine can be discontinued abruptly without tapering, as it does not require a gradual dose reduction. 1

Key Discontinuation Guidance

The FDA-approved prescribing information explicitly states that "Atomoxetine capsules can be discontinued without being tapered." 1 This is fundamentally different from many other psychiatric medications that require gradual dose reduction.

Clinical Considerations When Stopping

Monitoring After Discontinuation

  • Symptom rebound assessment: While atomoxetine discontinuation does not cause withdrawal symptoms, ADHD symptoms will return as the medication effect wears off 2
  • Timeline for symptom return: Monitor for return of inattention, hyperactivity, or impulsivity over the first 1-2 weeks after stopping 2
  • Discontinuation is well tolerated: Research shows a low incidence of discontinuation-emergent adverse events with atomoxetine 2

Important Distinctions from Other Medications

Unlike SSRIs (which can cause discontinuation syndrome with dizziness, nausea, and sensory disturbances) 3 or benzodiazepines (which require slow tapering to avoid withdrawal) 3, atomoxetine does not produce physiological withdrawal or discontinuation syndromes 1, 2.

Practical Implementation

  • Simply stop the medication: No dose reduction schedule is needed 1
  • Patient counseling: Inform the patient that ADHD symptoms will gradually return but no withdrawal symptoms should occur 2
  • Follow-up timing: Schedule reassessment within 2-4 weeks to evaluate symptom status and discuss alternative treatment if needed 3

Common Pitfall to Avoid

Do not confuse atomoxetine discontinuation with SSRI or stimulant discontinuation protocols. The absence of required tapering is a unique pharmacological property of atomoxetine related to its mechanism as a selective norepinephrine reuptake inhibitor without significant receptor binding 2, 4.

Related Questions

Can a patient use Straterra (atomoxetine) with a stimulant?
How soon can the dosage of Strattera (atomoxetine) 40mg daily be increased for Attention Deficit Hyperactivity Disorder (ADHD)?
Is 60mg of atomoxetine a suitable dose for treating Attention Deficit Hyperactivity Disorder (ADHD)?
What is the recommended dose of atomoxetine (Attention Deficit Hyperactivity Disorder - ADHD) medication when administered at night?
What is the appropriate next step for a 28-year-old patient with Attention Deficit Hyperactivity Disorder (ADHD) who reports no improvement after being started on atomoxetine (Strattera) 18mg?
What is the best treatment approach for a patient with a history of multi-drug resistant infections and previous linezolid recommendation for their current urinary tract infection?
What is the immediate treatment for a patient with severe abdominal bloating, severe pain, and abdominal distension, considering potential life-threatening conditions such as bowel obstruction, perforation, or severe inflammatory processes?
What is the prognosis for a stable adult patient with a history of bipolar disorder?
What is the best approach to diagnose Chronic Obstructive Pulmonary Disease (COPD) in a patient with a history of smoking or exposure to lung irritants and symptoms such as shortness of breath, wheezing, or chronic cough?
What is the recommended treatment for a patient with a positive Rapid Plasma Reagin (RPR) test result indicating syphilis?
Should a patient with microcytic anemia, as indicated by a Mean Corpuscular Volume (MCV) of 71.4, Mean Corpuscular Hemoglobin (MCH) of 21.4, Mean Corpuscular Hemoglobin Concentration (MCHC) of 30.0, and Red Cell Distribution Width (RDW) of 15.7, be started on oral iron supplements?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.